December 18, 2024

Doctor Unions Surge Tenfold Since 2023

The number of physicians seeking to unionize has spiked in recent years.

Conexiant

December 18, 2024

Physicians With Kids Face Large Pay Gaps

Physician compensation remains a central concern in health care, influenced by educational debt, specialty-specific variations, and evolving employer policies.

Conexiant

December 16, 2024

A Diagnosis of Lymphoma Has Changed My Life

“I was 35 when I was told that I had CD20-positive Hodgkin lymphoma. My oncologist assured me that although the disease was rare, it was treatable—and even curable. With the memory of my dying father ...

The ASCO Post

December 11, 2024

Triple-Drug Combos Show High Response Rates

Cutting-edge triple-drug therapies for leukemia discussed at the American Society of Hematology meeting show promising results in achieving remission and managing residual disease.

Reuters

December 11, 2024

Study Links cfDNA Sequencing to Cancer Detection

Nearly 50% of pregnant participants with abnormal cell-free DNA sequencing results were found to have undiagnosed cancers, highlighting the potential of prenatal cell-free DNA screening to detect occult cancers.

Conexiant

December 09, 2024

Oral Liquid Imatinib Approved by the FDA in Leukemia

The U.S. Food and Drug Administration (FDA) recently has approved an oral solution of the tyrosine kinase inhibitor, imatinib mesylate, called Imkeldi, to treat certain types of leukemia and other can...

The ASCO Post

December 04, 2024

UnitedHealthcare CEO Fatally Shot Outside NYC Hotel

Brian Thompson, the CEO of UnitedHealthcare's insurance unit, was fatally shot in the chest.

Reuters

December 02, 2024

2024 Vitamin D Guidelines: A Critical Review

"If the pharmaceutical industry had developed a single drug capable of reducing cancer mortality by 25%, autoimmune disorders by 39%, and COVID-19 infection rates by 74%, it would be heralded as a miracle drug."

Conexiant

November 27, 2024

Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1–Associated Plexiform Neurofibroma

In a phase IIb trial (ReNeu) reported in the Journal of Clinical Oncology, Moertel et al found that the CNS-penetrant small molecule MEK1/2 inhibitor mirdametinib showed activity in adults and childre...

The ASCO Post